Secondary objectives:~To evaluate the efficacy of cenobamate tablets and suspension in pediatric subjects with partial onset (focal) seizures~To evaluate the pharmacokinetics of cenobamate tablets and suspension in pediatric subjects with partial onset seizures~To evaluate the PK/pharmacodynamics of cenobamate in pediatric subjects with partial onset (focal) seizures~Acceptability and palatability assessment (determined by a 5-point Hedonic Scale) of the oral formulation and the 12.5 mg tablets - Day 1, and Day 15
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures